Ovid Therapeutics Insider RSU Award Signals Investor Confidence & Boosts Stock Potential
Ovid Therapeutics’ latest RSU grant to board member Stelios Papadopoulos signals insider confidence amid strong KCC2 clinical progress and an upcoming FDA IND filing, potentially boosting investor sentiment and stock momentum.
4 minutes to read